natgillin/translations-raw huggingface dataset:
In addition, virologic response was observed in 91% (21/23), 71% (15/21) and 33% (2/6) patients with 0 − 5, 6 − 7, and 8 
Uz to, virološki je odgovor uočen u, redom, 91% (21/23), 71% (15/21) i 33% (2/6) bolesnika s 0 − 5, 6 − 7 i 8 − 10 gore navedenih mutacija proteaze HIV-a povezanih sa smanjenom osjetljivošću na lopinavir in vitro.
Myalgia, musculoskeletal pain including arthralgia and back pain, muscle disorders such as weakness and spasms 
Mijalgija, bol u mišićnokoštanom sustavu uključujući artralgiju i bol u leđima, poremećaj mišića kao što su slabost i grčevi Manje često Rabdomioliza, osteonekroza
For monitoring of blood lipids and glucose, reference is made to established HIV treatment guidelines. 
Za nadzor lipida u krvi date su preporuke u utvrđenim smjernicama za liječenje HIV-a.
People taking lopinavir/ritonavir may still develop infections or other illnesses associated with HIV disease and AIDS. 
Ljudi koji uzimaju lopinavir/ritonavir mogu ipak razviti infekcije ili druge bolesti povezane s HIV bolesti i AIDS-om.
Marked triglyceride elevation is a risk factor for development of pancreatitis. 
Izrazito povišena razina triglicerida čimbenik je rizika od pankreatitisa.
− Always keep enough lopinavir/ritonavir on hand so you don't run out. 
Pazite da uvijek imate dovoljno lopinavira/ritonavira kako Vam ne bi ponestalo lijeka.
The pharmacokinetics of lopinavir/ritonavir oral solution 300/75 mg/m2 twice daily and 230/57.5 mg/m2 twice daily have been studied in a total of 53 paediatric patients, ranging in age from 6 months to 12 years. 
Farmakokinetika oralne otopine lopinavira/ritonavira u dozi od 300/75 mg/m² dvaput na dan i 230/57,5 mg/m² dvaput na dan ispitana je u ukupno 53 pedijatrijska bolesnika u dobi od 6 mjeseci do 12 godina.
HIV RNA < 400 copies/ml Mean increase from baseline in CD4+ T-cell count (cells/mm3) 
HIV RNA < 400 kopija/ml Srednja vrijednost porasta od početne vrijednosti u broju CD4+ T-stanica (stanica/mm3)
− Haemophilia type A and B as lopinavir/ritonavir might increase the risk of bleeding. 
Hemofiliju tip A ili tip B jer lopinavir/ritonavir može povećati rizik od krvarenja.
Due to the risk of QTc prolongation associated with DM-6705, if coadministration of delamanid with Lopinavir/Ritonavir Mylan is considered necessary, very frequent ECG monitoring throughout the full delamanid treatment period is recommended (see section 4.4 and refer to the delamanid SmPC). 
Zbog rizika od produljenja QTc intervala povezanog s DM-6705, ukoliko se istodobna primjena delamanida i lijeka Lopinavir/Ritonavir Mylan smatra nužnom, preporučuje se učestalo praćenje EKG-a bolesnika tijekom cijelog razdoblja liječenja delamanidom (vidjeti dio 4.4 i Sažetak opisa svojstava lijeka za delamanid).
M98-940 was an open-label study of a liquid formulation of lopinavir/ritonavir in 100 antiretroviral naïve (44%) and experienced (56%) paediatric patients. 
M98-940 bilo je otvoreno ispitivanje lopinavira/ritonavira u tekućem obliku u 100 pedijatrijskih bolesnika, od kojih neki prethodno nisu primali antiretrovirusne lijekove (44 %), a neki jesu (56 %).
After a 400/100 mg 14C-lopinavir/ritonavir dose, approximately 10.4 ± 2.3% and 82.6 ± 2.5% of an administered dose of 14C-lopinavir can be accounted for in urine and faeces, respectively. 
Nakon jednokratne doze od 400/100 mg 14C-lopinavira/ritonavira, oko 10,4 ± 2,3% primijenjene doze 14C-lopinavira nađeno je u urinu, a oko 82,6± 2,5 % u fecesu.
Co-administration of voriconazole and low dose ritonavir (100 mg BID) as contained in Lopinavir/Ritonavir Mylan tablets should be avoided unless an assessment of the benefit/risk to patient justifies the use of voriconazole. 
Mora se izbjegavati istodobna primjena vorikonazola i ritonavira u niskoj dozi (100 mg BID) kakvu sadrže tablete lijeka Lopinavir/Ritonavir Mylan, osim ako ocjena omjera koristi/rizika za bolesnika ne opravdava primjenu vorikonazola.
If this coadministration is judged unavoidable, increased dose of Lopinavir/Ritonavir Mylan at 400 mg/400 mg twice daily may be administered with rifampicin under close safety and therapeutic drug monitoring. 
Ocijeni li se da je ta kombinacija neizbježna, povećana se doza lijeka Lopinavir/Ritonavir Mylan od 400 mg/400 mg dvaput na dan smije davati istodobno s rifampicinom uz pažljiv nadzor neškodljivosti i terapijskog djelovanja lijeka tijekom liječenja.
One-hundred thirteen nelfinavir-treated patients and 74 lopinavir/ritonavir-treated patients had an HIV RNA above 400 copies/ml while on treatment from Week 24 through Week 96. 
113 bolesnika liječenih nelfinavirom i 74 bolesnika liječenih lopinavirom/ritonavirom imali su HIV RNA iznad 400 kopija/ml tijekom liječenja od 24 do 96 tjedna.
Most tyrosine kinase inhibitors such as dasatinib and nilotinib, also vincristine and vinblastine: 
Većina inhibitora tirozin kinaze kao što su dasatinib i nilotinib, također vinkristin i vinblastin:
M06-802 was a randomised open-label study comparing the safety, tolerability and antiviral activity of oncedaily and twice daily dosing of lopinavir/ritonavir tablets in 599 subjects with detectable viral loads while receiving their current antiviral therapy. 
M06-802 je bilo randomizirano, otvoreno ispitivanje koje je uspoređivalo sigurnost, podnošljivost i antivirusnu aktivnost kod doziranja lopinavir/ritonavir tableta jednom dnevno i doziranja dva puta dnevno kod 599 ispitanika s mjerljivom količinom virusa za vrijeme primanja njihove antivirusne terapije.
Isolates retained susceptibility to tipranavir with a median increase of IC50 in baseline and rebound isolates of 1.9- and 1.8-fold, respectively, compared to wild type virus. 
Izolirani sojevi zadržali su osjetljivost na tipranavir s medijanom porasta IC50 od 1,9 puta u sojeva na početku i 1,8 puta u izoliranih sojeva kod ponovnog porasta broja virusa u odnosu na divlje sojeve virusa.
Caution must also be exercised and reduced doses should be considered if lopinavir/ritonavir is used concurrently with rosuvastatin. 
Oprez je također nužan te se mora razmotriti smanjenje doze ako se lopinavir/ritonavir daje istodobno s rosuvastatinom.
Consequently, concomitant administration of Lopinavir/Ritonavir Mylan and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4). 
Slijedom toga, ne preporučuje se istodobna primjena lijeka Lopinavir/Ritonavir Mylan i tih glukokortikoida, osim ako očekivana korist od liječenja ne nadmašuje rizik od učinaka sistemskih kortikosteroida (vidjeti dio 4.4).
Immunosuppressants Cyclosporin, Sirolimus (rapamycin), and Tacrolimus 
Immunosupresivi Ciklosporin, sirolimus (rapamicin) i takrolimus
Recommended lopinavir/ritonavir dosing (mg) twice daily. 
Preporučena doza lopinavira/ritonavira (mg) dva puta dnevno.
In another open-label pharmacokinetic study, 19 HIV-infected pregnant women received lopinavir/ritonavir 400/100 mg twice daily as part of combination antiretroviral therapy during pregnancy from before conception. 
U drugom otvorenom farmakokinetičkom ispitivanju je 19 trudnica inficiranih HIV-om uzimalo 400 mg/100 mg lopinavira/ritonavira dvaput na dan kao dio kombinirane terapije antiretrovirusnim lijekovima tijekom trudnoće, a koja je započeta prije začeća.
The adverse clinical signs observed in dogs included salivation, emesis and diarrhoea/abnormal stool. 
Klinički znakovi predoziranja zabilježeni u pasa obuhvaćaju pojačanu salivaciju, povraćanje i proljev/nenormalnu stolicu.
Concomitant use of lopinavir/ritonavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4, such as budesonide and triamcinolone, is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression (see section 4.5). 
Ne preporučuje se istodobna primjena lopinavira/ritonavira i flutikazona ni drugih glukokortikoida koji se metaboliziraju putem CYP3A4, kao što su budezonid i triamcinolon, osim ako očekivana korist od liječenja nadmašuje rizik od sistemskih učinaka kortikosteroida, uključujući pojavu Cushingov sindrom i supresiju nadbubrežne žlijezde (vidjeti dio 4.5).
Due to the risk of bedaquiline related adverse events, the combination of bedaquiline and Lopinavir/Ritonavir Mylan should be avoided. 
Zbog povećanog rizika od štetnog događaja povezanog s bedakilinom, kombinacija bedakilina i lijeka Lopinavir/Ritonavir Mylan se mora izbjegavati.
The in vitro antiviral activity of lopinavir against laboratory and clinical HIV strains was evaluated in acutely infected lymphoblastic cell lines and peripheral blood lymphocytes, respectively. 
Antivirusna aktivnost lopinavira na laboratorijske i kliničke sojeve HIV-a ispitivano je na akutno inficiranim limfoblastičnim staničnim lozama i limfocitima iz periferne krvi in vitro.
Co-administration of increased doses of fosamprenavir (1400 mg BID) with lopinavir/ritonavir (533/133 mg BID) to protease inhibitor-experienced patients resulted in a higher incidence of gastrointestinal adverse events and elevations in triglycerides with the combination regimen without increases in virological efficacy, when compared with standard doses of fosamprenavir/ritonavir. 
Istodobna primjena većih doza fosamprenavira (1400 mg BID) i lopinavira/ritonavira (533/133 mg BID) kod bolesnika koji su već primali inhibitore proteaza, rezultirala je povećanjem učestalosti gastrointestinalnih štetnih događaja i povišenjem vrijednosti triglicerida dok se virološka djelotvornost pritom nije povećala, u usporedbi sa standardnim dozama fosamprenavira/ritonavira.
When Lopinavir/Ritonavir Mylan is administered concomitantly with bosentan, the efficacy of the HIV therapy should be monitored and patients should be closely observed for bosentan toxicity, especially during the first week of coadministration. 
Pri istodobnoj primjeni lijeka Lopinavir/Ritonavir Mylan s bosentanom, mora se pratiti djelotvornost liječenja HIV-a te pomno pratiti bolesnike zbog toksičnosti bosentana, osobito tijekom prvog tjedna istodobne primjene.
Lopinavir AUC over a 24 hour dosing interval averaged 206.5 ± 89.7 μg h/ml. 
Vrijednost AUC lopinavira je tijekom 24 satnog doziranja prosječno bila 206,5 ± 89,7 μg·h/ml.
How much Lopinavir/Ritonavir Mylan should be taken and when? 
Kada i koliko Lopinavir/Ritonavir Mylan treba uzimati?
Ombitasvir/paritaprevir/rito navir + dasabuvir 
Ombitasvir/paritaprevir/ ritonavir + dasabuvir
The Lopinavir/Ritonavir Mylan dose should be titrated upward only after rifampicin has been initiated (see section 4.4). 
Doza lijeka Lopinavir/Ritonavir Mylan smije se povećavati tek nakon uvođenja rifampicina (vidjeti dio 4.4).
Lopinavir: ↔ (Relative to 400/100 mg BID administered alone) 
Lopinavir: ↔ (U odnosu na 400/100 mg BID primijenjen sam)
The selection of resistance to lopinavir in patients having failed prior protease inhibitor therapy was characterised by analysing the longitudinal isolates from 19 protease inhibitor-experienced subjects in 2 Phase II and one Phase III studies who either experienced incomplete virologic suppression or viral rebound subsequent to initial response to lopinavir/ritonavir and who demonstrated incremental in vitro resistance between baseline and rebound (defined as emergence of new mutations or 2-fold change in phenotypic susceptibility to lopinavir). 
Analiza rezistencije u bolesnika liječenih inhibitorima proteaze Rezistencija na lopinavir u bolesnika u kojih prethodna terapija inhibitorom proteaze nije uspjela određena je analizom longitudinalnih izolata 19 bolesnika koji su prethodno bili na terapiji inhibitorom proteaze iz dva istraživanja faze II i jednog istraživanja faze III, a u kojih je zamjećena ili nepotpuna virusna supresija ili ponovni porast broja virusa (rebound) nakon početnog odgovora na lopinavir/ritonavir te u kojih je primjećen in vitro porast rezistencije u fazi ponovnog porasta broja virusa (definiran kao pojava nove mutacije ili dvostruka promjena fenotipske osjetljivosti na lopinavir) u odnosu na početak.
Cushing's syndrome has been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway e.g. budesonide (see section 4.4 and 4.5). 
Chushingov sindrom je zabilježen kod bolesnika kojima je tijekom uzimanja ritonavira davan flutikazonpropionat inhalacijski ili intranazalno; to se također može dogoditi i s ostalim kortikosteroidima, koji se metaboliziraju preko P450 3A npr. budezonid (vidjeti dijelove 4.4 i 4.5).
Co-administration of ibrutinib and Lopinavir/Ritonavir Mylan may increase ibrutinib exposure which may increase the risk of toxicity including risk of tumor lysis syndrome. 
Istodobna primjena ibrutiniba i lijeka Lopinavir/Ritonavir Mylan može povećati izloženost ibrutinibu što može povećati rizik od toksičnosti uključujući rizik od sindroma tumorske lize.
The lopinavir mean steady-state AUC, Cmax, and Cmin were 72.6 ± 31.1 μg•h/ml, 8.2 ± 2.9 μg/ml and 3.4 ± 2.1 μg/ml, respectively after lopinavir/ritonavir oral solution 230/57.5 mg/m2 twice daily without nevirapine (n=12), and were 85.8 ± 36.9 μg•h/ml, 10.0 ± 3.3 μg/ml and 3.6 ± 3.5 μg/ml, respectively after 300/75 mg/m2 twice daily with nevirapine (n=12). 
Srednje vrijednosti AUC, Cmax, i Cmin lopinavira u ravnotežnom stanju pri uzimanju oralne otopine lopinavira/ritonavira u dozi od 230/57,5 mg/m² dvaput na dan bez nevirapina (n=12) iznosile su, redom, 72,6 ± 31,1 µg•h/ml, 8,2 ± 2,9 µg/ml i 3,4 ± 2,1 µg/ml, dok su pri uzimanju oralne otopine lopinavira/ritonavira u dozi od 300/75 mg/m² dvaput na dan s nevirapinom (n=12) iznosile, redom, 85,8 ± 36,9 µg•h/ml, 10,0 ± 3,3 µg/ml i 3,6 ± 3,5 µg/ml.
HIV-1 has been passaged in vitro with lopinavir alone and with lopinavir plus ritonavir at concentration ratios representing the range of plasma concentration ratios observed during lopinavir/ritonavir therapy. 
HIV-1 inkubiran je in vitro s lopinavirom samim, te s lopinavirom i ritonavirom u omjerima koncentracija koje su oponašale omjere koncentracija u plazmi izmjerene pri uzimanju lopinavira/ritonavira.
Lopinavir/ritonavir 800/200 mg QD was administered with ombitasvir/paritaprevir/ritonavir with or without dasabuvir. 
Lopinavir/ritonavir 800/200 mg QD primijenjen je s ombitasvirom/paritaprevirom/ritona virom s dasabuvirom ili bez njega.
Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin. 
Upozorava se na pojačano praćenje nuspojava povezanih s rifabutinom uključujući neutropeniju i uveitis zbog povećane izloženosti rifabutinu.
The following table contains dosing guidelines for lopinavir/ritonavir 100/25 mg tablets based on body weight and BSA. 
Sljedeća tablica sadrži smjernice za doziranje 100/25 mg tableta lopinavira/ritonavira temeljeno na tjelesnoj težini i površini tijela.
Particular caution should be used when prescribing Lopinavir/Ritonavir Mylan in patients taking digoxin as the acute inhibitory effect of ritonavir on Pgp is expected to significantly increase digoxin levels. 
Osobito je nužan oprez pri propisivanju lijeka Lopinavir/Ritonavir Mylan bolesnicima koji već uzimaju digoksin jer se očekuje da će se značajno povećati razine digoksina zbog akutnog inhibicijskog učinka ritonavira na Pgp.
Most tyrosine kinase inhibitors such as dasatinib and nilotinib, vincristine, vinblastine 
Većina inhibitora tirozin kinaze kao što su dasatinib i nilotinib, Vinkristin, Vinblastin
Initiation of digoxin in patients already taking Lopinavir/Ritonavir Mylan is likely to result in lower than expected increases of digoxin concentrations. 
Pri uvođenju digoksina bolesnicima koji već uzimaju Lopinavir/Ritonavir Mylan, koncentracije digoksina vjerojatno će porasti manje nego što se očekuje.
Lopinavir/ritonavir must not be given to these patients (see section 4.3). 
Lopinavir/ritonavir se tim bolesnicima ne smije davati (vidjeti dio 4.3).
- Multipack containing 360 (3 bottles of 120) film-coated tablets. 
- Višestruka pakiranja koje sadrži 360 (3 boce sa 120) filmom obloženih tableta.
Incremental resistance was most common in subjects whose baseline isolates had several protease inhibitor-associated mutations, but < 40-fold reduced susceptibility to lopinavir at baseline. 
Porast rezistencije bio je češći u bolesnika čiji su početni izolati imali nekoliko uz inhibitore vezanih mutacija, ali početnu osjetljivost na lopinavir manju od četrdeseterostruke.
BGP Products UAB Tel: +370 5 205 1288 
BGP Products UAB Tel: + 370 5 205 1288 (Jungtinė Karalystė)
≥ 0.9 to < 1.4 
 0,9 do < 1,4
Refer to the afatinib SmPC for dosage adjustment recommendations. 
Vidjeti Sažetak opisa svojstava lijeka za afatinib za preporuke za prilagodbu doze.
Patients were administered at least two nucleoside/nucleotide reverse transcriptase inhibitors selected by the investigator. 
Prema odabiru ispitivača bolesnicima su davana najmanje dva nukleozidna/nukletidna inhibitora reverzne transkriptaze.
It is important that Lopinavir/Ritonavir Mylan tablets are swallowed whole and not chewed, broken or crushed. 
Važno je da tablete Lopinavir/Ritonavir Mylan progutate cijele, nemojte ih žvakati, lomiti ili drobiti.
Co-administration of rivaroxaban and Lopinavir/Ritonavir Mylan may increase rivaroxaban exposure which may increase the risk of bleeding. 
Istodobna primjena rivaroksabana i lijeka Lopinavir/Ritonavir Mylan može povećati izloženost rivaroksabanu što može povećati rizik od krvarenja.
Lopinavir/ritonavir tablets can be taken with or without food. 
Tablete lopinavira/ritonavira se mogu uzeti s ili bez hrane.
Lopinavir/ritonavir tablets are administered orally and must be swallowed whole and not chewed, broken or crushed. 
Tablete lopinavira/ritonavira se primjenjuju peroralno i moraju se progutati čitave te se ne smiju žvakati, lomiti ili drobiti.
HIV RNA < 50 copies/ml*† Mean increase from baseline in CD4+ T-cell count (cells/mm3) 207 * intent to treat analysis where patients with missing values are considered virologic failures † p<0.001 
Srednja vrijednost porasta od početne vrijednosti u broju CD4+ T-stanica (stanica/mm3) * analiza svih bolesnika koji su predviđeni za liječenje u ispitivanju (intent to treat analysis), u kojoj su bolesnici s nedostajućim vrijednostima smatrani kao virloški neuspjeh † p < 0.001
Lopinavir/ritonavir 800/200 mg was administered in combination with emtricitabine 200 mg and tenofovir DF 300 mg as part of a once-daily regimen. 
Lopinavir/ritonavir 800/200 mg je davana u kombinaciji s 200 mg emtricitabina i 300 mg tenofovira DF kao dio liječenja jednom dnevno.
Before prescribing lopinavir/ritonavir 100/25 mg tablets, infants and young children should be assessed for the ability to swallow intact tablets. 
Prije propisivanja 100/25 mg tableta lopinavira/ritonavira, mora se procijeniti mogu li mala djeca progutati cijelu tabletu.
Study M05-730 was a randomised, open-label, multicentre trial comparing treatment with lopinavir/ritonavir 800/200 mg once daily plus tenofovir DF and emtricitabine versus lopinavir/ritonavir 400/100 mg twice daily plus tenofovir DF and emtricitabine in 664 antiretroviral treatment-naïve patients. 
Studija M05-730 je bila randomizirano, otvoreno (''open-label''), multicentrično ispitivanje, u kojem se uspoređivalo liječenje lopinavirom/ritonavirom 800/200 mg jednom dnevno plus tenofovir DF i emtricitabinom naspram lopinavira/ritonavira 400/100 mg dva puta dnevno plus tenofovir DF i emtricitabin u 664 bolesnika koji prethodno nisu koristili antiretrovirusnu terapiju.
≥ 1.2 to < 1.4 
 1,2 do < 1,4
Careful monitoring of adverse effects (notably respiratory depression but also sedation) is recommended when fentanyl is concomitantly administered with Lopinavir/Ritonavir Mylan. 
Preporučuje se pažljivo promatranje štetnih događaja (prvenstveno depresije disanja ali i sedacije) u slučajevima gdje se fentanil daje zajedno s lijekom
If the co-administration of Lopinavir/Ritonavir Mylan with bupropion is judged unavoidable, this should be done under close clinical monitoring for bupropion efficacy, without exceeding the recommended dosage, despite the observed induction. 
Ako se istodobna primjena lijeka Lopinavir/Ritonavir Mylan s bupropionom ocijeni neizbježnom, lijekove treba davati uz pomno kliničko praćenje djelotvornosti bupropiona, pazeći da se unatoč opaženoj indukciji ne prekorače preporučene doze.
No age or gender related pharmacokinetic differences have been observed in adult patients. 
U odraslih bolesnika nisu uočene razlike u farmakokinetici s obzirom na dob niti s obzirom na spol.
At steady state, lopinavir protein binding remains constant over the range of observed concentrations after 400/100 mg lopinavir/ritonavir twice daily, and is similar between healthy volunteers and HIV-positive patients. 
U stanju dinamičke ravnoteže, vezanje lopinavira ostaje konstantno u rasponu koncentracija koje se postižu pri uzimanju lopinavira/ritonavira u dozi od 400/100 mg dvaput na dan, i istovjetno je između zdravih dragovoljaca i bolesnika s HIV-om.
Thyroid-stimulating hormone (TSH) should be monitored in patients treated with levothyroxine at least the first month after starting and/or ending ritonavir treatment. 
U bolesnika liječenih levotiroksinom potrebno je pratiti razinu tiroidnog stimulirajućeg hormona (TSH) najmanje tijekom prvih mjesec dana nakon početka i/ili završetka liječenja ritonavirom.
Other medicines and Lopinavir/Ritonavir Mylan 
Drugi lijekovi i Lopinavir/Ritonavir Mylan
Cmax: ↓ (relative to indinavir 800 mg TID alone) 
(u odnosu na indinavir 800 mg TID sam)
The risk of diarrhoea may be greater with once daily dosing of lopinavir/ritonavir. 
Rizik od proljeva se može povećati s doziranjem lopinavira/ritonavira jednom dnevno.
≥ 0.5 to < 0.8 
 0,5 do < 0,8
≥ 0.5 to < 0.9 
 0,5 do < 0,9
Therefore, if coadministration of delamanid with lopinavir/ritonavir is considered necessary, very frequent ECG monitoring throughout the full delamanid treatment period is recommended (see section 4.5 and refer to the delamanid SmPC). 
Stoga, ukoliko se istodobna primjena delamanida i lopinavira/ritonavira smatra nužnom, preporučuje se vrlo učestalo praćenje EKG-a bolesnika tijekom cijelog razdoblja liječenja delamanidom (vidjeti dio 4.5 i Sažetak opisa svojstava lijeka za delamanid).
Indeed, lopinavir/ritonavir could increase concentrations of the co-administered medicinal products and this may result in an increase of their associated cardiac adverse reactions. 
Lopinavir/ritonavir može povisiti koncentracije tih istodobno primijenjenih lijekova, zbog čega se može povećati i učestalost srčanih nuspojava povezanih s tim lijekovima.
Lopinavir AUC over a 12 hour dosing interval averaged 113.2 ± 60.5 μg•h/ml. 
AUC lopinavira pri doziranju u razmacima po 12 sati iznosila je 113,2 ± 60,5 μg•h/ml.
The effect on DAAs and lopinavir was similar to that observed when lopinavir/ritonavir 400/100 mg BID was administered (see section 4.3). 
Učinak na antivirusne lijekove s direktnim djelovanjem (DAA) i lopinavir bio je sličan onom opaženom pri primjeni lopinavira/ritonavira 400/100 mg BID (vidjeti dio 4.3).
MARKETING AUTHORISATION NUMBER EU/1/15/1067/004 - 120 Film-coated tablets EU/1/15/1067/006 - 120x1 Film-coated tablets EU/1/15/1067/005 - 360 Film-coated tablets 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/15/1067/004 - 120 filmom obloženih tableta EU/1/15/1067/006 - 120 x 1 filmom obloženih tableta EU/1/15/1067/005 - 360 filmom obloženih tableta
In contrast, similar concentrations of lopinavir/ritonavir demonstrated no repolarisation delay in the canine cardiac Purkinje fibres. 
Nasuprot tome, lopinavir/ritonavir u tim istim koncentracijama nisu odgodili repolarizaciju Purkinjeovih vlakana iz psećeg srca.
Experienced patients received nevirapine plus up to two nucleoside reverse transcriptase inhibitors. 
Bolesnici koji su prethodno već bili liječeni, primali su nevirapin plus i do dva nenukleozidna inhibitora reverzne transkriptaze.